Director and Management Shareholding Notifications
DXS INTERNATIONAL PLC
(AQSE: DXSP)
Notification of Director and Management Transactions
DXS International PLC, a prominent name in clinical decision support systems, has reported vital updates regarding share transactions by its Director. Mr. Bob Sutcliffe, who serves as the Chairman, has made noteworthy purchases in the company's stock, indicating his commitment and confidence in the future of DXS International.
Details of Recent Share Transactions
On 30 October 2024, it was disclosed that Mr. Sutcliffe acquired a total of 50,000 Ordinary Shares at a price of 1.0p each. Following that, on 31 October 2024, he further increased his stake by purchasing an additional 133,333 Ordinary Shares at 1.5p per share. After these transactions, Mr. Sutcliffe, along with his wife's holdings, represents an ownership of 1,116,719 Ordinary Shares, which accounts for approximately 1.74% of the company’s total issued share capital. This kind of personal investment by a key figure illustrates a strong belief in the company's mission and potential growth.
About DXS International PLC
DXS International PLC operates as a clinical decision support developer, delivering tailored systems to enhance clinical decision-making processes within healthcare settings. The company is committed to providing healthcare professionals with timely and relevant information sourced from Clinical Commissioning Groups and other reputable NHS organizations. By integrating these guidelines into everyday workflows, DXS aims to facilitate more effective and efficient patient care, contributing significantly to the overall healthcare landscape.
Impact of Director Transactions
Director shareholding notifications are crucial for stakeholders as they offer insights into the confidence executives have in their company's future. Mr. Sutcliffe's recent investments not only signal his personal faith in DXS International's trajectory but also reflect broader market expectations. Such transactions often influence public perception, potentially driving greater interest among investors and improving overall market confidence.
Contact Information
For any inquiries regarding this announcement or further details on DXS International, the following contacts are available:
David Immelman
DXS International PLC
Contact: 01252 719800
AQSE Corporate Broker and Corporate Advisor
Hybridan LLP
Contact: Claire Louise Noyce at 020 3764 2341
Frequently Asked Questions
What recent share purchases did the chairman make?
The chairman, Mr. Bob Sutcliffe, purchased 50,000 shares on 30 October 2024 and 133,333 shares on 31 October 2024.
What percentage of the company does Mr. Sutcliffe now own?
After his recent transactions, he owns approximately 1.74% of DXS International’s total issued share capital.
What does DXS International do?
DXS International provides clinical decision support systems that integrate treatment guidelines for healthcare professionals.
Who can I contact for more information on DXS International?
You can contact David Immelman at DXS International or Claire Louise Noyce from Hybridan LLP for inquiries.
Why are director shareholding notifications important?
They provide insights into executive confidence and can positively influence market perception and investor interest in a company.
